Journal Menu
Submit Manuscript via ScholarOne

Eurasian Journal of Analytical Chemistry
Volume 2, Issue 1 (March 2007), pp. 32-53

DOI: 10.12973/ejac.2007.00009a

Downloaded 6560 times.

Research Article

Published online on Jun 28, 2016

How to reference this article?

 

Impurity profile: Significance in Active Pharmaceutical Ingredient

Sanjay B. Bari, Bharati R. Kadam, Yogini S. Jaiswal, Atul A. Shirkhedkar

Abstract

Various regulatory authorities like ICH, USFDA, Canadian Drug and Health Agency are emphasizing on the purity requirements and the identification of impurities in Active Pharmaceutical Ingredient’s (API’s). Qualification of the impurities is the process of acquiring and evaluating data that establishes biological safety of an individual impurity; thus, revealing the need and scope of impurity profiling of drugs in pharmaceutical research.

Identification of impurities is done by variety of Chromatographic and Spectroscopic techniques, either alone or in combination with other techniques. There are different methods for detecting and characterizing impurities with TLC, HPLC, HPTLC, AAS etc. Conventional Liquid Chromatography, particularly, HPLC has been exploited widely in  field of impurity profiling; the wide range of detectors, and stationary phases along with its sensitivity and cost-effective separation have attributed to its varied applications. Among the various Planar Chromatographic Methods; TLC is the most commonly used separation technique, for isolation of impurities; due to its ease of operation and low cost compared to HPLC. An advancement of thin layer chromatography HPTLC, is a well-known technique for the impurity isolation.

Headspace GC is one of the most preferred techniques for identification of residual solvents. The advent of hyphenated techniques has revolutionized impurity profiling, by not only separation but structural identification of impurities as well. Among all hyphenated techniques, the most exploited techniques, for impurity profiling of drugs are LC-MS-MS, LC-NMR, LC-NMR-MS, GC-MS, and LC-MS.


References
  1. Alsante K M, Boutres P, Couturier M A, Fridmann R C, Harwood J W, Horan G J, Jensen A J, Liu Q, Lohr L L, Morris R, Raggon J W, Reid G L, Santafianos D P, Sharp T R, Tucker J L and Wilcox G E (2004) Pharmaceutical Impurity Identification: A Case Study Using a Multidisciplinary Approach. Journal of Pharmaceutical Sciences 93 (9): 2296.
  2. International Conference on Harmonization (2000) Draft Revised Guidance On Impurities In New Drug Substances. Federal Register Q3A(R) 65 (140): 45085.
  3. International Conference on Harmonization (2000) Draft Revised Guidance On Impurities In New Drug Products. Federal Register Q3B(R) 65 (139): 44791.
  4. International Conference on Harmonization (1997) Impurities, Q3C- Guidelines for Residual Solvents, Q3C. Federal Register 62(247): 67377.
  5. International Conference on Harmonization (1999) Specifications, Q6A: Test Procedures and Acceptance Criterial for New Drug Substances and New Drug Products. Chemical substances 65 (146):67488.
  6. Ahuja S (1998) Impurities Evaluation of Pharmaceuticals. Marcel Dekker, New York, p. 142.
  7. Gorog S (2000) Identification and Determination of Impurities in Drugs. Elsevier Science Publishing Company, Amsterdam, p.154.
  8. Alsante K M, Hatajik T D, Lohr L L and Sharp T R (2001) Isolation and Identification of Process Related Impurities and Degradation Products from Pharmaceutical Drug Candidates. Part 1, American Pharmaceutical Review 4(1): 70.
  9. Lohr L L, Sharp T R, Alsante K M and Hatajik T D (2001) Isolation and Identification of Process Related Impurities and Degradation Products from Pharmaceutical Drug Candidates. Part II: The Roles of NMR and Mass Spectrometry. American Pharmaceutical Review. Fall issue, Available at: http://http://www.americanpharmaceuticalreview.com/past_articles_f.htm
  10. Winger B E, Kemp C A (2001) Characterization of Pharmaceutical Compounds and Related Substances by using FTICR-MS and Tandem Mass Spectrometry, American Pharmaceutical Review. Summer issue, Available at: http://http://www.americanpharmaceuticalreview.com/past_articles_f.htm
  11. ICH Topic Q3 A (1995) Impurities Testing Guideline: Impurities in New Drug Substances, The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit.
  12. Farmer S, Anderson P, Burns P and Velagaleti R Forced (2002) Degradation of Ibuprofen in Bulk Drugs and Tablets. Pharmaceutical Technology 28: 42.
  13. Bhat P and Velingkar V S (2004) Synthesis and Characterization of Degradation Products in Diclofenac-Na and Clotrimazole. Indian Drugs 40 (7): 396.
  14. Volk K J, Hill S E, Kerns E H, Lee M S (1997) Profiling degradants of paclitaxel using liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry substructural techniques. J Chromatogr B 696(1):99:
  15. Riley T N (1998) Steric aspects of drug action. Pharmacist 23(3): 40.
  16. Jacobs P, Dewe W, Flament A, Gibella M, Ceccato A (2005) A new validation approach applied to the GC determination of impurities in organic solvents. J Pharm Biomed Anal 40:294.
  17. Jack Yuk K Cheng, Man Fai Chan, Tai Wai Chan, Mei Yuen Hung., Impurity profiling of ecstasy tablets seized in Hong Kong by GC-MS, (2006), Article in Press Forensic Science International 144:21
  18. Gimeno P, Besacier F, Bottex M, Dujourdy L, Chaudron-Thozet H, A study of impurities in intermediates and 3, 4 methylenedioxymethamphetamine (MDMA) samples produced via reductive amination routes, (2005), Forensic Science International 155:141
  19. Buhler V (1998) Vademecum for Vitamin Formulation. Stuttgart, Germany, Wiss, Verl-Ges., 142:36
  20. Food and Drug Administration for Immediate Release Consumer Media (1998) 888- Info- FDA. May 6, p. 45
  21. Hoq M M, Morsheda S B and Gomes D J (1991) Development of appropriate preservative system for liquid antacid: bacterial contaminants in antacid samples. J Microbio 8(1): 5
  22. Roy J, Islam M, Khan A H, Das S C, Akhteruzzaman M, Deb A K, Alam A H (2001) Diclofenac sodium injection sterilized by autoclave and the occurrence of cyclic reaction producing a small amount of impurity. J Pharma Sci 90: 541
  23. Roy J, Mahmud M, Sobhan A, Aktheruzzaman M, Al-Faooque M and Ali E (1994) Marketed vitamin B-complex injectables: stability and mutual interaction. Drug Dev Ind Pharm 20(13): 2157
  24. Conner K A, Amidon G L and Stella V J (1986) Chemical Stability of Pharmaceuticals-A Handbook of Pharmacists. New York: John Willey & Sons, p. 458
  25. Hoerle S L, Evans K D and Snider B G (1992) HPLC Determination of Impurities in a 3rd Generation Cephalosporine, Eastern Analytical Symposium, November 16-20, Somerset, New Jersey. 12
  26. Gazdag M, Babjag M, Brlik J, Maho S, Tuba Z and Gorog S (1998) Estimation of profile of drug and related materials Part 18. Impurities and degradation product of mazipredone. J Pharm Biomed Anal 17:1029
  27. Roy J, Bhuiyan K, Faraque A, Sobahan M, Al-Farooque M (1997) Injectable ergometrine: stability and packaging for developing countries. Indian Drugs 34(11): 634
  28. Kumar V, Sunder N and Potdar A (1992) Critical factors in developing pharmaceutical formulations-An overview. Part II. Pharma Tech 16:86
  29. Smith A, Pennefather P M, Kaye S B and Hart C A (2001) Fluroquinolones- place in ocular therapy. Indian Drugs 61(6): 747
  30. Roy J, Das S C, The effect of sunlight on ciprofloxacin eye drops., In press, p. 14
  31. Condorelli G, De Guidi G, Giulfrido S, Sortino S, Chilleni R and Sciuto S (1999) Molecular mechanics of photosensitization induced by drugs XII. Photochemistry and photosensitization of rufloxacin: An unsual photo degradation path for the antibacterials containing a Fluoroquinolones- like chromophore, Photochemistry and Photobiology 70(3): 280.
  32. Sanga S V (1979) Review of glass types available for packaging parenteral solutions. J Parenteral Drug Assn 33:61. 
  33. Paskier D (1997) Strategy for determining extractable from rubber packaging materials in drug products. J Pharm Sci 51:248.
  34. Hamon M (1981) Plastic materials in pharmaceutical packaging I: Behaviour in relation to various parameters. Sci Tech Pharm 10: 277.
  35. Malamatais S, Tsiri K and Goidas P (1992) Sorption of moisture of different size fraction of some direct compression excipients and tensile strength of corresponding tablets, Congr. Int Technol Pharm 6th, 5:195:204.
  36. Aignasse M F, Prognon P, Stachowicz M, Gheyouche R and Pradeau D (1995) A new and rapid HPLC method for determination of DEHP in PVC packaging and releasing studies. Int J Pharm113: 241.
  37. Fras I, Cassagnau P and Michel A (1998) Influence of processing conditions on the leaching of thermal stabilizers from plasticized poly (vinyl chloride) in the presence of water. J Appl Polym Sci 70:2391.
  38. Repmeyer J C and Juhl Y H (2001) Contamination of injectable solutions with 2- mercaptobenzothiazole leached from rubber closures. J Pharm Sci 2:1302.
  39. Hartauer K J, Mayer R F, Schwier J R, Bucko J H, Cooke G G and Ad Sullivan G R (1993) The effect of rayon coiler on the dissolution stability of hard-shell gelatine capsules. Pharm Tech 17 (76- 80):82.
  40. Ahuja S and Scypinski S (2001) Handbook of Modern Pharmaceutical Analysis, Academic Press, NY, p. 298
  41. Ahuja S, (1997) Chiral Separations by Chromatography, Oxford University Press, NY, p 365
  42. Ahuja S (1992) Chromatography of Pharmaceuticals: Natural, Synthetic and Recombinant Products. ACS Symposium Series #512, Ame Chem Soc, Washington, DC, p. 14.
  43. Ahuja S (1992) Trace and Ultra trace Analysis by HPLC, Willey, New York, p. 84
  44. Peter J S, Ahmed A and Yan W (2006) An HPLC chromatographic reactor approach for investigating the hydrolytic stability of a pharmaceutical compound. J Pharm Biomed Anal 41: 883. 
  45. Radhakrishna T, Satynarayana J and Satynarayana A (2002) Determination of Loratidine and its Related Impurities by HPLC. Indian Drugs 39 (6): 342.
  46. Radhakrishna T, Satynarayana J and Satynarayana A (2002) HPLC method for the Degradation of Celecoxib and its Related Impurities. Indian Drugs 40(3): 166.
  47. Zawilla N H, Li B, Hoogmartens J and Adams E (2006) Improved RP-LC method combined with pulsed electrochemical detection for the analysis of amikacin. J Pharm Biomed Anal 42: 114.
  48. Nisha M, Ismail M, Ismail R, Duncan F, Maili L, Jeremy K N and John C L (1999) Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements. J Pharm Biomed Anal 19:511.
  49. Fiori J, Bragieri M, Zanotti M C, Liverani A, Borzatta V, Mancini F, Cavrini V and Andrisano V (2005) LC-TMS for the identification of impurities in d-allethrine samples. J Chromatogr A 1099:149.
  50. Ravindra Kumar Y, Moses Babu J, Sharma M S P (2003) Seshidhar B, Srinivasa Reddy S, Sudarsan Reddy G and Vyas K, Application of LC-MS/MS for the identification of the polar impurity in mosapride, a gastroprokinetic drug. J Pharm Biomed Anal 32:361.
  51. Tetsuro S and Yukiko M (2006) Effective injection in pulsed splittless mode for impurity profiling of methamphetamine crystal by GC or GC/MS. Forensic Science International 161:1.
  52. Joachim E (1998) The use of hyphenated LC-MS technique for characterization of impurity profiles during drug development. J Pharm Biomed Anal 18:707.
  53. Sattanathan P, Moses Babu S, Vyas K, Reddy R B, Rajan S T and Sudhakar P (2006) Structural studies of impurities of risperidone by hyphenated techniques. J Pharm Biomed Anal 40:598.
  54. Rudaz S, Souverain S, Schelling C, Deleers M, Klomp A, Norris A, Vu T L, Ariano B and Veuthey J L (2003) Development and validation of heart-cutting liquid chromatography mass- spectrometry method for determination of process-related substances in cetrizine tablets. Anal Chim Acta 492:271.
  55. British Pharmacopoeia (2004) The Department of Health, Social Services and Public Safety
  56. Indian Pharmacopoeia (1996) Government of India, Ministry of Health and Family Welfare. Published by the Controller of Publications, Delhi.
  57. United State Pharmacopeia (2004) The National Formulary. Asian Edition .
  58. Halmos Z, Szantay C, Brlik J J, Csehi A, Varga K, Horvath P, Kislaki M, Domani G, Nemes A and Gorog S (1996) Estimation of impurity profile of drugs and related materials Part 15. Identification of minor impurities in cimetidine. J Pharm Biomed Anal 15: 1.
  59. Horvath P, Balogh G, Brlik J, Csehi A, Dravecz F, Halmos Z, Lauko A, Renyei M, Varga K and Gorog S (1997) Estimation of impurity profile of drugs and related materials Part 16: identification of the side-products of the ethinylation step in the synthesis of contraceptive gestogens. J Pharm Biomed Anal 15:1343
  60. Satyanarayana U, Sreenivas Rao D, Ravindra Kumar Y, Moses Babu J, Rajender Kumar P and Tirupathi Reddy J (2004) Isolation, synthesis and characterization of impurities in celecoxib a COX-2 inhibitor. J Pharm Biomed Anal 35: 951.
  61. Babjak M, Balogh G, Gazdag M and Gorog S (2002) Estimation of impurity profile of drugs and related materials Part XXI. HPLC/UV/MS study of the impurity profile of ethynodiol diacetate. J Pharm Biomed Anal 29:1153
  62. Vichet P, Narini S, Juthamard P, Wiphada P, Tetsuro S and Ken T (2002) Idetification of impurities and statistical classification of methamphetamine tablets (Ya-Ba) seized in Thailand. Forensic Science International 126:105
  63. Krishna Reddy K V S R, Moses Babu J, Vijayvitthal T M, Eswaraiah S, Satyanarayana Reddy M, Dubey P K and Vyas K (2003) Impurity profile study of repaglinide. J Pharm Biomed Anal 32:461
  64. Dams R, Benijts T, Lambert W, Massart D and De Leenheer A (2001) Heroin impurity profiling: trends throughout a decade of experimenting-Review. Forensic Science International 121:81
  65. Kelly S, Padraig M G, Stuart J M and David H G (2003) An impurity in a morphine sulphate drug product identified is 5-(Hydroxymethyl)-2-furfural, 10- Hydroxymorphine and 10-Oxomorphine. J Pharm Biomed Anal 92:485 
  66. Analytical procedures and methods validation chemistry, manufacturing, and controls documentation- Guidance Document (2000) U.S. Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER).
  67. Ms. Meera S H, Impurity Profile: A Review Pharmainfo_net (2005) available at: http://www.pharmainfo.net/exclusive/reviews/impurity_profile: A Review.
  68. Analytical Procedures and Methods Validation Chemistry (2000) Manufacturing, and Controls Documentation- Guidance Document U. S. Food Drug and Administration. Center for Biologics Evaluation and Research (CBER).
  69. Gorog S (2006) The importance and challenges of impurity profiling in modern pharmaceutical analysis. Trends in Analytical Chemistry, p. 755.